Key facts
- Namida Lab’s last known valuation is $20.1M (Aug 2021).
- It has raised $30.1M across 1 recorded rounds; the latest was Early Stage VC ($5.0M) in Aug 2019.
- Notable investors include Capital Factory, Tech4Eva.
- Namida Lab has filed 1 Form D with the SEC, most recently Aug 2021 ($5.0M sold to 4 investors).
- Status: Privately Held (backing).
Investors
2- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Namida Lab
Funding rounds
1 roundsAbout Namida Lab
Developer of a cancer screening and diagnostic tool designed for early detection using proteins found in tears. The company developed a screening test for breast cancer that analyzes proteins from tears, operates a certified high-complexity lab to process cancer screening samples, and operates a separate research and development lab to perform product development, enabling women to access affordable breast health screening and stay healthy.
- Sector
- Healthcare
- HQ
- Fayetteville, AR, United States
- Founded
- 2019
- Employees
- 10
- Website
- namidalab.com/
- Ownership
- Privately Held (backing)
Namida Lab doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Namida Lab shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Namida Lab in its N-PORT filings yet. We sweep new filings monthly.